The Vascular Endothelial Growth Factor (VEGF) Inhibitor by The Business Research Company provides market overview across 60+ geographies in the seven regions - Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa, encompassing 27 major global industries. The report presents a comprehensive analysis over a ten-year historic period (2010-2021) and extends its insights into a ten-year forecast period (2023-2033).
Learn More On The Vascular Endothelial Growth Factor (VEGF) Inhibitor Market:
https://www.thebusinessresearchcompany.com/report/vascular-endothelial-growth-factor-inhibitors-global-market-report
%20Inhibitor.jpg)
According to The Business Research Company’s Vascular Endothelial Growth Factor
(VEGF) Inhibitor, The vascular endothelial growth factor (vegf) inhibitor
market size has grown strongly in recent years. It will grow from $9.68 billion
in 2023 to $10.46 billion in 2024 at a compound annual growth rate (CAGR) of
8.0%. The growth in the historic period can be
attributed to increase in cancer prevalence, strong economic growth in emerging
markets, increase in pharmaceutical r&d expenditure, increased healthcare
expenditure, government initiatives and rapid growth in elderly population.
The vascular endothelial growth factor (vegf) inhibitor market size is expected
to see strong growth in the next few years. It will grow to $13.98 billion in
2028 at a compound annual growth rate (CAGR) of 7.5%. The growth in the forecast period can be
attributed to increasing prevalence of cancer, rising prevalence of age-related
macular degeneration (amd), rise in healthcare expenditure, high potential of
emerging economies, high penetration of the biosimilar drugs and increasing
geriatric population. Major trends in the forecast period include offering
combination therapies to patients in order to combat advanced cancers and
improve patient life, focusing on strategic collaborations to boost innovations
and establish category leadership, investing extensively in r&d activities
for the development of effective and innovative drugs, focusing on the
production of biosimilars in order to cater to a wider market by making treatment
more affordable and focusing on reducing dosages for wet age-related macular
degeneration (amd) in order to improve patient welfare.
The growing prevalence of cancer and macular degeneration diseases is expected
to drive the VEGF inhibitor market. For instance, in August 2022, according to
this systematic review and meta-analysis published by the National Library of
Medicine, a US-based medical library, age-related macular degeneration will
affect 8–7% of the global population, with the illness affecting 196 million
individuals in 2020 and rising to 288 million by 2040. Anti-vascular
endothelial growth factor (anti-VEGF) agents halt the progression of the
disease and improve vision. A vascular endothelial growth factor (VEGF)
inhibitor slows and restricts tumor growth during cancers. Hence, the rising
prevalence of cancer along with macular degeneration disease aids in the
vascular endothelial growth factor (VEGF) inhibitor market growth over the
forecast period.
Get A Free Sample Of The Report (Includes Graphs And Tables):
https://www.thebusinessresearchcompany.com/sample.aspx?id=3437&type=smp
The vascular endothelial growth factor (vegf) inhibitor market covered in this
report is segmented –
1) By Drugs Type: Avastin, Tecentriq, Lucentis, Tagrisso, Cometriq, Eylea,
Other Drug Types
2) By Route Of Administration: Oral, Intravenous, Intravitreal
3) By Application: Oncology, Ophthalmology, Other Applications
Key players operating in the VEGF inhibitor industry are undergoing various
collaborations and partnerships to expand their product portfolio by developing
new products. Product portfolio expansion is the strategic approach that
companies use to grow their businesses and increase their market share by
satisfying consumer demand. The process of product development includes
conceptualization, design, development, and marketing of newly created or newly
rebranded goods or services. For instance, in September 2021, AbbVie, a
US-based pharmaceutical company, partnered with REGENXBIO Inc., a US-based
biotechnology company, to develop and commercialize RGX-314, an experimental
gene therapy for chronic retinal illnesses such as diabetic retinopathy, wet
age-related macular degeneration, and others. RGX-314 consists of the NAV AAV8
vector, which encodes an antibody fragment designed to inhibit vascular
endothelial growth factor (VEGF). It is believed that RGX-314 blocks the VEGF
pathway, which is responsible for the development of new, leaky blood vessels
and the subsequent fluid buildup in the retina. In accordance with the terms of
the contract, AbbVie will make a $370 million upfront payment to REGENXBIO,
with the possibility of subsequent payments totaling up to $1.38 billion upon
achievement of additional development, regulatory, and commercial
milestones.
The vascular endothelial growth factor (vegf) inhibitor market report table of
contents includes:
1. Executive Summary
2. Vascular
Endothelial Growth Factor (VEGF) Inhibitor Market Characteristics
3. Vascular
Endothelial Growth Factor (VEGF) Inhibitor Market Trends And Strategies
4. Vascular
Endothelial Growth Factor (VEGF) Inhibitor Market - Macro Economic Scenario
5. Global
Vascular Endothelial Growth Factor (VEGF) Inhibitor Market Size and Growth
.
32. Global Vascular Endothelial Growth Factor (VEGF) Inhibitor Market
Competitive Benchmarking
33. Global
Vascular Endothelial Growth Factor (VEGF) Inhibitor Market Competitive
Dashboard
34. Key
Mergers And Acquisitions In The Vascular Endothelial Growth Factor (VEGF)
Inhibitor Market
35.
Vascular Endothelial Growth Factor (VEGF) Inhibitor Market Future Outlook and
Potential
36.
Appendix
Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: info@tbrc.info
Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
Facebook: https://www.facebook.com/TheBusinessResearchCompany
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Blog: https://blog.tbrc.info/
Healthcare Blog: https://healthcareresearchreports.com/
Global Market Model:
https://www.thebusinessresearchcompany.com/global-market-model
No comments:
Post a Comment